Please select the option that best describes you:
How would you treat a patient with biopsy-proven recurrent urothelial bladder cancer with M1a disease (limited to retroperitoneal nodal disease)?
NCCN guidelines suggest systemic therapy only or concurrent chemoradiotherapy. What is your approach?
Answer from: Medical Oncologist at Academic Institution
Systemic therapy with either clinical trial, or chemotherapy (ideally cisplatin-based or carboplatin/gemcitabine if cisplatin-unfit), or immune checkpoint inhibitor (if it is first line treatment setting and cisplatin-unfit, options include either pembrolizumab or atezolizumab, if either 'PD-L1 high...
Sign in or Register to read more